Objectives: The coronavirus disease 2019 (COVID-19) has significantly impacted health care delivery across the United States, including treatment of cancer. We aim to describe the determinants of treatment plan changes from the perspective of oncology physicians across the United States during the COVID-19 pandemic. Methods: Participants were recruited to an anonymous cross-sectional online survey of oncology physicians (surgeons, medical oncologists, and radiation oncologists) using...
Fri Aug 28, 2020 03:00
Introduction: With an increasing number of systemic therapy options for hepatocellular carcinoma (HCC), optimal sequencing is an important consideration. There remains limited real-world data about the eligibility of patients for second-line therapies in advanced HCC. We characterized real-world eligibility and use of second-line therapies post sorafenib. Materials and Methods: We identified all patients with advanced HCC who received ≥1 cycle of first-line sorafenib between January...
Fri Aug 28, 2020 03:00
In the past few years, the immune checkpoint inhibitor (ICI) nivolumab has become standard of care in the treatment of metastatic renal cell carcinoma (mRCC) progressing after antiangiogenic agents. To date, neither expression of programmed death ligand-1 (PD-L1) nor any other biomarker can be used to predict responses to ICIs, although intermediate–poor International Metastatic Database of Renal Carcinoma (IMDC) risk patients and those with sarcomatoid tumors appear to achieve superior benefit from...
Thu Aug 27, 2020 03:00
Background Tumor human epidermal growth factor receptor 2 (HER2) status is defined by either protein expression using immunohistochemistry (IHC) or gene amplification using fluorescence in situ hybridization (FISH). Approximately 20% of HER2-positive breast cancer is HER2 IHC 2+/FISH-positive. Unlike trastuzumab, it has not been studied whether the response to trastuzumab emtansine (T-DM1) differs according to HER2-positive status. Methods We retrospectively identified and reviewed...
Thu Aug 27, 2020 03:00
Anaplastic lymphoma kinase (ALK)-translocations are present in up to 5% of non-small cell lung cancer (NSCLC), most of them being adenocarcinomas. Even though the availability of five potent ALK-inhibitors for the treatment of ALK-positive NSCLC patients, there is no consensus about the ideal therapy sequence. Alectinib has been so far successfully and routinely used as first-line therapy, especially in patients presenting central nervous system lesions; however, with the very recent European approval...
Thu Aug 27, 2020 03:00
Inflammatory myofibroblastic tumour (IMT) is a rare malignancy with limited responses to corticosteroids and chemotherapy. About half of cases have activating rearrangements in the ALK gene which could be targeted with ALK inhibitors. A 40-year-old man presented with a large right lung mass and nodal, trapezius and cerebral metastases. Biopsy confirmed IMT with TPM4-ALK fusion. He was treated with prednisolone without clinical benefit. He received the Trk/ROS1/ALK inhibitor entrectinib in a clinical...
Thu Aug 27, 2020 03:00
Malignant melanoma is a kind of highly invasive and deadly diseases. The BRAF inhibitor (BRAFi) such as vemurafenib could achieve a high response rate in melanoma patients with BRAFV600E mutation. However, melanoma cells could easily develop resistance as well as addiction to BRAFi. Based on the drug addiction, intermittent treatment has been proposed to select against BRAFi-resistant melanoma cells. Because different dosages of BRAFi might be used in patients, it is necessary to know about the relationship...
Thu Aug 27, 2020 03:00
Long noncoding RNA (lncRNA) testis-specific transcript, Y-linked 15 (TTTY15) plays an important regulatory role in prostate cancer, but its role in esophageal squamous cell carcinoma (ESCC) remains unclear. This study aimed to explore the expression pattern, biological function and underlying mechanism of TTTY15 in ESCC. Quantitative real-time PCR (qRT-PCR) was used to detect the expression of TTTY15 and microRNA (miR)-337-3p in ESCC tissues and cell lines. Cell counting kit-8 method was used to...
Thu Aug 27, 2020 03:00
British Journal of Cancer, Published online: 01 September 2020; doi:10.1038/s41416-020-01044-8Real-world outcomes treating patients with advanced cutaneous squamous cell carcinoma with immune checkpoint inhibitors (CPI)
03:00
British Journal of Cancer, Published online: 01 September 2020; doi:10.1038/s41416-020-01033-xPre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trials
03:00
British Journal of Cancer, Published online: 01 September 2020; doi:10.1038/s41416-020-01045-7The nucleolar-related protein Dyskerin pseudouridine synthase 1 (DKC1) predicts poor prognosis in breast cancer
03:00
Publication date: October 2020Source: European Journal of Cancer, Volume 138Author(s): Martin Salzmann, Ulrike Leiter, Carmen Loquai, Lisa Zimmer, Selma Ugurel, Ralf Gutzmer, Kai-Martin Thoms, Alexander H. Enk, Jessica C. Hassel
Mon Aug 31, 2020 17:17
Publication date: October 2020Source: European Journal of Cancer, Volume 138Author(s): Marc Pujalte-Martin, Fanny Rocher, Nathalie Cardot-Leccia, Damien Giacchero, Delphine Borchiellini
Mon Aug 31, 2020 17:17
Publication date: October 2020Source: European Journal of Cancer, Volume 138Author(s): Manar Yanes, Giola Santoni, John Maret-Ouda, Eivind Ness-Jensen, Martti Färkkilä, Elsebeth Lynge, Bright Nwaru, Eero Pukkala, Pål Romundstad, Laufey Tryggvadóttir, My von Euler-Chelpin, Jesper Lagergren
Mon Aug 31, 2020 17:17
Publication date: October 2020Source: European Journal of Cancer, Volume 138Author(s): Shiliang Liu, Jing Wen, Hong Yang, Qiaoqiao Li, Yuping Chen, Chengchu Zhu, Wentao Fang, Zhentao Yu, Weimin Mao, Jiaqing Xiang, Yongtao Han, Lei Zhao, Hui Liu, Yonghong Hu, Mengzhong Liu, Jianhua Fu, Mian Xi
Mon Aug 31, 2020 17:17
Abstract ObjectivePrognostic awareness is essential for making treatment decisions in malignant diseases. Being confronted with a poor prognosis, however, can affect patients' mental health. Therefore, it is important to study coping in the context of malignant diseases. Acceptance is an adaptive coping strategy associated with less psychological distress. This study sought to explore the facilitators and barriers for prognostic acceptance in a sample in which both hope and uncertainty regarding...
Sun Aug 30, 2020 20:14
Early-stage primary gastrointestinal (GI) low-grade B-cell lymphoma shows good therapeutic response to primary radiotherapy. However, there is no clear guideline for the evaluation of response to radiation the...
Mon Aug 31, 2020 03:00
Publication date: Available online 30 August 2020Source: Seminars in OncologyAuthor(s): Whitney Hensing, Cesar A. Santa-Maria, Lindsay L. Peterson, Jennifer Sheng
Mon Aug 31, 2020 16:13
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.